Under the terms of the agreement, Miraculins will combine its internal research expertise with the research capabilities and patient network of Duke University Medical Center (DUMC).
The collaboration with DUMC, under the direction of Lead Investigator Dr Judd Moul, professor and the chief of Urological Surgery at DUMC, will allow for the refinement and confirmation of results from the discovery phase of Miraculins’ prostate cancer diagnostic project.
These results were recently presented at the American Association for Cancer Research International Conference on Molecular Targets and Cancer Therapeutics, and included company developed algorithms and several biomarkers.
“There is a critical need for new molecular biomarkers to help us to better care for our patients with cancer. For prostate cancer in particular, the problem is magnified due to the widely varying behavior of these cancers in individual men”, stated Dr Moul, lead investigator on the study.